Skip to main content
. Author manuscript; available in PMC: 2018 Dec 15.
Published in final edited form as: Clin Cancer Res. 2018 Sep 17;24(24):6223–6229. doi: 10.1158/1078-0432.CCR-18-1687

Fig. 1: Study Concept.

Fig. 1:

(A) 24–48 hours prior to a planned core decompression for ON treatment, patients received an intravenous injection of the FDA-approved iron supplement ferumoxytol. (B) Ferumoxytol is taken up by cells in normal bone marrow, leading to hypointense (dark) signal on MRI. (C) 24–48 hours after iron supplement administration, iron labeled bone marrow cells were harvested from the iliac crest during core decompression. (D) The osteonecrotic bone was decompressed by drilling a track to the ON through a minimally invasive procedure and (E) iron labeled bone marrow cells were injected through the decompression track.